Hepatitis B immunoglobulin in preventing reinfection following liver transplantation

References

• Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the Hepatitis B surface antigen. N. Engl. J. Med.329, 1842–1847 (1993).
   PubMed Web of Science ®Google Scholar
• O’Grady JG, Smith HM, Davies S et al. Hepatitis B virus infection after orthotopic liver transplantation. J. Hepatol.14, 104–111 (1992).
   PubMed Web of Science ®Google Scholar
• Ottobrelli A, Marzano A, Smedile A et al. Patterns of hepatitis d virus reinfection and disease in liver transplantation. Gastroenterology101, 1649–1655 (1991).
   PubMed Web of Science ®Google Scholar
• Todo S, Demetris AJ, Van TD et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology13, 619–626 (1991).
   PubMed Web of Science ®Google Scholar
• Anselmo DM, Ghobrial RM, Jung LC et al. New era of liver transplantation for hepatitis B. Ann. Surg.235, 611–619 (2002).
   PubMed Web of Science ®Google Scholar
• Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology24, 1327–1333 (1996).
   PubMed Web of Science ®Google Scholar
• Muller R, Gubernatis G, Farle M et al. Liver transplantation in HBs antigen carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J. Hepatol.13, 90–96 (1991).
   PubMed Web of Science ®Google Scholar
• Nymann T, Adamec T, Shokouh-Amiri MH et al. Detection of recurrent hepatitis B after OLT in patients treated with HBIG prophylaxis using graft-biopsy staining, anti-HBs titers and hepatitis B serology. Transplant. Proc.29, 507–508 (1997).
   PubMed Web of Science ®Google Scholar
• Grazi GL, Mazziotti A, Sama C et al. Liver transplantation in HBsAg-positive HBV-DNA-negative cirrhotics: immunoprophylaxis and long-term outcome. Liver Transpl. Surg.2, 418–425 (1996).
   PubMedGoogle Scholar
• Omata M. Significance of extrahepatic replication of hepatitis B virus. Hepatology12, 364–366 (1990).
   PubMed Web of Science ®Google Scholar
• Dienstag J, Isselbacher K. Acute hepatitis. In: Harrison’s Principle of Internal Medicine (13th Edition). Issenbacher K (Ed.). McGrawHill, NY, USA, 1458–1463 (1994).
   Google Scholar
• Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet337, 813–815 (1991).
   PubMed Web of Science ®Google Scholar
• Naumann U, Protzer-Knolle U, Berg T et al. A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high-dose anti-hepatitis B virus surface antigen immunoprophylaxis. Hepatology26, 478–484 (1997).
   PubMedGoogle Scholar
• Perillo RP, Mason AL. Hepatitis B and liver transplantation. Problems and promises. N. Engl. J. Med.329, 1885–1887 (1993).
   PubMed Web of Science ®Google Scholar
• Marzano A, Salizzoni M, Bernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J. Hepatol.34, 903–910 (2001).
   PubMed Web of Science ®Google Scholar
• McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation61, 1358–1364 (1996).
   PubMed Web of Science ®Google Scholar
• Sawyer RG, McGory RW, Gaffey MJ et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann. Surg.227, 841–850 (1998).
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Keefe EB, Han S et al. Prevention of recurrent hepatitis B infection following liver transplantation: experience in 112 North American patients. Hepatology30, 301A (1999).
   Google Scholar
• Perillo RP, Rakela J, Schiff E et al. A multicenter United States–Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology33, 424–432 (2001).
   PubMed Web of Science ®Google Scholar
• Fischer L, Sterneck M, Meire D et al. The use of antiviral monotherapy and combination therapy for patients with hepatitis B virus infection after liver transplantation. Transplant. Proc.34, 2283–2284 (2002).
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology28, 585–589 (1998).
   PubMed Web of Science ®Google Scholar
• Yoshida H, Kato T, Levi DM et al. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin. Transplant.21, 166–171 (2007).
   PubMed Web of Science ®Google Scholar
• Starkel P, Cicarelli O, Lerut J et al. Limited lamivudine and long-term hepatitis B immunoprophylaxis for prevention of hepatitis B recurrence after liver transplantation. Transplantation74, 408–410 (2002).
   PubMed Web of Science ®Google Scholar
• Angus PW, McCaughan GW, Gane EJ et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post-transplantation hepatitis B. Liver Transpl.6, 429–433 (2000).
   PubMed Web of Science ®Google Scholar
• Yoshida EM, Erb SR, Partovi N et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl. Surg.5, 520–525 (1999).
   PubMedGoogle Scholar
• Han SH, Ofman J, Holt C et al. An efficacy and cost–effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immuneglobulin monotherapy. Liver Transpl.6, 741–748 (2000).
   PubMed Web of Science ®Google Scholar
• Dickson RC, Terrault NA, Ishitani M et al. Protective antibody levels and dose requirements for IV 5% Nabi hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl.12, 124–133 (2006).
   PubMed Web of Science ®Google Scholar
• Hayashi MS, Cooke J, Imagawa DK. Importance of continued hepatitis B immunoglobulin in preventing reinfection following transplantation. Presented at: Joint International Congress of ILTS, ERLITA, and LICAGE, Milan, Italy, 3–6 May 2006.
   Google Scholar
• Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology132, 931–937 (2007).
   PubMed Web of Science ®Google Scholar
• Wong SN, Chu C-J, Wai C-T et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl.13, 374–381 (2007).
   PubMed Web of Science ®Google Scholar
• Terrault NA, Kilic M, Karademir S et al. HepaGam B after liver transplant in patients with hepatitis B virus. US Gastroenterol. Rev.2, 40–45 (2007).
   Google Scholar
• HepaGAM B®, prescribing information. Cangene, Winnepeg, Canada, January 2006.
   Google Scholar
• Siegel J. The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy25, 78S–84S (2005).
   PubMed Web of Science ®Google Scholar
• Siegel J. Safety considerations in IGIV utilization. Int. Immunopharmacol.6, 523–527 (2006).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Renal insufficiency and failure associated with immune globulin intravenous therapy: United States, 1985–1998. MMWR Morb. Mortal. Wkly Rep.48, 518–521 (1999).
   PubMedGoogle Scholar
• EMEA – Committee for Proprietary Medicinal Products (CPMP). Core SPC for human plasma derived hepatitis-B immunoglobulin for intravenous use. Draft guidelines, London, UK, 24 July 2003.
   Google Scholar
• Roche B, Feray RJ, Moore C et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology38, 86–95 (2003).
   PubMed Web of Science ®Google Scholar
• Chu CJ, Fontana RJ, Moore C et al. Outcome of liver transplantation for hepatitis B: report of a single center’s experience. Liver Transpl.8, 724–731 (2001).
   Google Scholar
• Honaker MR, Shokouh-Amiri MH, Vera SR et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl. Infect. Dis.3, 137–143 (2002).
   Google Scholar
• Buti M, Mas A, Prieto M et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIG) and lamivudine with long-term lamivudine plus HBIG in the prevention of hepatitis B virus recurrence after liver transplantation. J. Hepatol.38, 811–817 (2003).
   PubMed Web of Science ®Google Scholar
• Yao FY, Osirio RW, Roberts JP et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl. Surg.6, 491–496 (1999).
   Google Scholar
• Dodson SF, de Vera ME, Bonham CA et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl.6, 434–439 (2000).
   PubMed Web of Science ®Google Scholar
• Albeniz AE, Barcena MR, Oton NE et al. Use of combined treatment of hepatitis B immune globulin and lamivudine as prevention of hepatitis B virus recurrence in liver allograft. Transplant. Proc.35, 1844–1845 (2003).
   PubMed Web of Science ®Google Scholar
• Engler S, Sauer P, Klar E et al. Prophylaxis of hepatitis B recurrence after liver transplantation with lamivudine and hepatitis B immunoglobulin. Transplant. Proc.34, 2285–2287 (2002).
   PubMed Web of Science ®Google Scholar
• Dumortier J, Chevallier P, Scoazec JY et al. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am. J. Transplant.8, 999–1002 (2003).
   Google Scholar
• Ben-Ari Z, Mor E, Bar-Nathan N et al. Combination hepatitis B immune globulin and lamivudine versus hepatitis B immune globulin monotherapy in preventing recurrent hepatitis B virus infection in liver transplant recipients. Transplant. Proc.35, 609–611 (2003).
   PubMed Web of Science ®Google Scholar
• Lee PH, Hu RH, Tsai MK et al. Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine. Transplant. Proc.32, 2245–2247 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenau J, Bahr MJ, Tillmann HL et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation: possible role of mutations in the YMDD motif prior to transplantation as a risk factor for re-infection. J. Hepatol.34, 895–902 (2001).
   PubMed Web of Science ®Google Scholar
• Dan YY, Wai CT, Yeoh KG et al. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost–effectiveness analysis. Liver Transpl.12, 736–746 (2006).
   PubMed Web of Science ®Google Scholar
• Azoulay D, Linhares MM, Huguet E et al. Decision for retransplantation of the liver. Experience- and cost-based analysis. Ann. Surg.236, 713–721 (2002).
   PubMed Web of Science ®Google Scholar
• Terrault NA, Roche B, Samuel D. Management of hepatitis B virus in the liver transplant setting: a European and an American perspective. Liver Transpl.11, 716–732 (2005).
   PubMed Web of Science ®Google Scholar
• Angus PW, Patterson SJ, Strasser SI et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology5, 1460–1466 (2008).
   Google Scholar